Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CBPO China Biologic Products (CBPO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About China Biologic Products Stock (NASDAQ:CBPO) 30 days 90 days 365 days Advanced Chart Ad Golden CrestBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Get CBPO alerts:Sign Up Key Stats Today's Range$118.24▼$120.0550-Day Range$117.88▼$119.9952-Week Range$99.74▼$120.05Volume24,016 shsAverage Volume148,695 shsMarket Capitalization$4.72 billionP/E Ratio33.52Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewChina Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China.Read More… Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?Click Here For Your Free Guide Receive CBPO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for China Biologic Products and its competitors with MarketBeat's FREE daily newsletter. Email Address CBPO Stock News HeadlinesHow is China changing?August 5, 2024 | bbc.co.ukChina hits back at Trump with tariffs on $60bn of US goodsDecember 14, 2023 | bbc.comLet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! November 17, 2024 | DTI (Ad)Biologic Excipients industry research covers a wide range of industries with predicted CAGR 10% during 2023-2030June 22, 2023 | marketwatch.comNerve Biologic Products Market 2023-2030: Future Hypothesize and ascending UpdatesMay 6, 2023 | marketwatch.comBiologic Excipients Market by 2030: Future Scope and PredictionsApril 16, 2023 | marketwatch.comWhat is the US’ ‘One China’ policy, and why is it important?April 14, 2023 | nypost.comNerve Biologic Products Market in 2023: Insights and Strategies | 2029April 9, 2023 | marketwatch.comSee More Headlines CBPO Stock Analysis - Frequently Asked Questions How were China Biologic Products' earnings last quarter? China Biologic Products Holdings, Inc. (NASDAQ:CBPO) released its quarterly earnings results on Sunday, March, 28th. The biopharmaceutical company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.22. The biopharmaceutical company earned $112.10 million during the quarter. China Biologic Products had a net margin of 27.43% and a trailing twelve-month return on equity of 8.32%. What other stocks do shareholders of China Biologic Products own? Based on aggregate information from My MarketBeat watchlists, some other companies that China Biologic Products investors own include Meta Platforms (META), Bristol-Myers Squibb (BMY), NVIDIA (NVDA), Lexicon Pharmaceuticals (LXRX), Gilead Sciences (GILD), Alibaba Group (BABA) and Pfizer (PFE). Company Calendar Last Earnings3/28/2021Today11/17/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CBPO CUSIPN/A CIK1369868 Webwww.chinabiologic.com Phone861065983111FaxN/AEmployees2,269Year Founded1989Profitability EPS (Most Recent Fiscal Year)$4.28 Trailing P/E Ratio33.52 Forward P/E Ratio30.93 P/E GrowthN/ANet Income$138.81 million Net Margins27.43% Pretax MarginN/A Return on Equity8.32% Return on Assets7.64% Debt Debt-to-Equity RatioN/A Current Ratio12.01 Quick Ratio10.13 Sales & Book Value Annual Sales$503.70 million Price / Sales9.38 Cash Flow$5.01 per share Price / Cash Flow23.93 Book Value$45.09 per share Price / Book2.66Miscellaneous Outstanding Shares39,360,000Free FloatN/AMarket Cap$4.72 billion OptionableOptionable Beta0.47 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CBPO) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Biologic Products Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Biologic Products With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
